Skip to product information
1 of 1

Zoetis

RespiSure 1 One

RespiSure 1 One

Regular price $33.10 USD
Regular price Sale price $33.10 USD
Sale Sold out
Size
Size: 50 Dose, 250 Dose, and 500 Dose bottles
For vaccination of healthy swine 1 day of age or older as an aid in preventing chronic Pneumonia caused by Mycoplasma hyopneumoniae.

Dosage: 2 ml IM. Semi-annual revaccination with a single dose of RespiSure One is recommended.

Manufacturer and/or Label Information

ZOETIS INC.
333 PORTAGE STREET, KALAMAZOO, MI, 49007
Telephone: 269-359-4414
Customer Service: 888-963-8471
Website: www.zoetis.com
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.
RespiSure 1 ONE®

Zoetis

Mycoplasma Hyopneumoniae Bacterin

For use in swine only

PRODUCT DESCRIPTION: RespiSure-ONE is for vaccination of healthy swine 1 day of age or older as an aid in reducing chronic pneumonia caused by Mycoplasma hyopneumoniae. Duration of immunity in 1-day-old pigs has not been established.

RespiSure-ONE is a liquid preparation of a chemically inactivated whole cell culture of M. hyopneumoniae, coupled with a unique oil adjuvant Amphigen®, to enhance and prolong the immune response without causing detectable tissue damage at the injection site.

DISEASE DESCRIPTION: Mycoplasmal pneumonia of swine (MPS) or enzootic pneumonia is a widespread, chronic disease characterized by coughing, growth retardation, and reduced feed efficiency. The etiologic agent is M. hyopneumoniae; however, the naturally occurring disease often results from a combination of bacterial and mycoplasmal infections.

MPS causes considerable economic loss in all areas where swine are raised. Surveys conducted at various locations throughout the world indicate that lesions typical of those seen with MPS occur in 30%-80% of slaughter-weight swine. Because mycoplasmal lesions may resolve before hogs reach slaughter weight, the actual incidence may be higher. The prevalence of M. hyopneumoniae infection in chronic swine pneumonia has been reported to range from 25%1-93%.2 Pigs of all ages are susceptible to MPS, but the disease is most common in growing and finishing swine. Current evidence indicates that M. hyopneumoniae is transmitted by aerosol or direct contact with respiratory tract secretions from infected swine. Transmission from sow to pig during lactation is possible.3 Once established, MPS occurs year after year in infected herds, varying in severity with such environmental factors as season, ventilation, and concentration of swine.

Clinical signs of MPS include a chronic, nonproductive cough continuing for weeks or months, unthrifty appearance, and retarded growth, even though the appetites of infected swine remain normal. Stunting may occur, resulting in considerable variation in size among affected pigs. Death loss associated with secondary bacterial infection and stress may occur.

M. hyopneumoniae causes a loss of ciliary motility in the bronchial passages. Eventually the cilia are destroyed, resulting in reduction in natural defense in the upper respiratory tract and increased susceptibility to secondary infection with bacterial agents such as Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae, and Bordetella bronchiseptica. Swine lungworm and roundworm larvae infections may also increase the severity of MPS.

SAFETY AND EFFICACY: In clinical studies conducted by Zoetis Inc., RespiSure- ONE has been shown to be safe and free from significant adverse reactions when administered according to label directions. Chemical inactivation renders RespiSure-ONE incapable of causing infectious disease. The oil-base adjuvant in RespiSure-ONE does not produce the major tissue damage sometimes associated with conventional oil adjuvants.

Efficacy of RespiSure-ONE was demonstrated in host animal studies conducted by Zoetis Inc.; duration-of-immunity studies demonstrated efficacy up to 25 weeks after a single vaccination in pigs as young as 1 week of age. In all of these duration-of-immunity studies, pigs vaccinated with RespiSure-ONE, followed by challenge, had significantly lower lung lesion scores than pigs vaccinated with a placebo.

Duration-of-immunity studies: The purpose of the 7 studies below in Table 1 was to demonstrate protection against challenge with virulent M. hyopneumoniae 8, 18, 23 or 25 weeks after a single vaccination with RespiSure-ONE in 1-, 3-, or 8-week-old pigs. All pigs were necropsied and lung lesion scores determined (percent of total lung with lesions4). In all cases pigs vaccinated with RespiSure-ONE had significantly lower lung lesion scores than pigs

vaccinated with a placebo. Duration of immunity in 1-day-old pigs has not been established.

Table 1.

Study

Treatment

No. of Pigs

Vaccination (age in wks)

Challenge (wks after vacc)

Challenge (age in wks)

% Lung Lesion

1

Placebo

22

3

8

11

2.7a

RespiSure-ONE

24

3

8

11

0.1b

2

Placebo

20

3

18

21

13.2a

RespiSure-ONE

19

3

18

21

5.5b

3

Placebo

18

8

8

16

10.3a

RespiSure-ONE

20

8

8

16

0.5b

4

Placebo

21

8

18

26

9.6a

RespiSure-ONE

20

8

18

26

0.9b

5

Placebo

19

3

23

26

9.0a

RespiSure-ONE

22

3

23

26

2.1b

6

Placebo

26*

1

25

26

4.5a

RespiSure-ONE

22*

1

25

26

2.0b

7

Placebo

24

1

25

26

5.9a

RespiSure-ONE

20

1

25

26

0.3b

a,b Within each study group, values with different superscripts are statistically significant vs. placebo (p≤0.05).

* Pigs were serologically positive for M. hyopneumoniae.

DIRECTIONS:

1. General Directions: Shake well. Aseptically administer 2 mL intramuscularly.

2. Primary Vaccination: Administer a single 2-mL dose to healthy swine 1 day of age or older. RespiSure-ONE may also be given as two 1-mL doses administered 2 weeks apart.

3. Revaccination: Semiannual revaccination with a single dose is recommended.

4. Good animal husbandry and herd health management practices should be employed.

PRECAUTIONS:

1. Store at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.

2. Use entire contents when first opened.

3. Sterilized syringes and needles should be used to administer this vaccine.

4. Do not vaccinate within 21 days before slaughter.

5. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

6. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

REFERENCES:

1. Gois M, Kuksa F, Sisak F: Microbiological findings in the lungs of slaughter pigs. Proc 6th Int Congr Pig Vet Soc, Copenhagen. 6:214, 1980.

2. Yamamoto K, Ogata M: Mycoplasmal and bacterial flora in the lungs of pigs. Proc 7th Int Congr Pig Vet Soc, Mexico City. 7:94, 1982.

3. Clark LK: Stalling mycoplasma. Hog Farm Management. p. 56, Oct 1988.

4. Pointon AM, Mercy AR, Backstrom L, Dial GD: Surveillance at Slaughter. In AD Leman, Straw BE, Mengeling WL, et al. (eds.) Diseases of Swine, 7th Edition, p 975. ISU Press, Ames Iowa USA.

Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471 (USA), (800) 461-0917 (Canada).

For veterinary use only

U.S. Veterinary License No.190

Zoetis Inc., Kalamazoo, MI 49007, USA

13954300

Presentation: 50 dose (100 mL), 250 dose (500 mL), and 500 dose (1,000 mL) bottles.

CPN: 3690034.5

COLORADO SERUM COMPANY4950 YORK STREET, P.O. BOX 16428, DENVER, CO, 80216-0428Telephone: 303-295-7527Order Desk: 800-525-2065Fax: 303-295-1923Website: www.colorado-serum.comEmail: colorado-serum@colorado-serum.comTHIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.

TETANUS TOXOID-CONCENTRATED

Colorado Serum

Adjuvanted

GENERAL INFORMATION: This product has been shown to be effective for the vaccination of healthy horses, cattle, sheep, goats, and swine against tetanus. This product was licensed prior to the requirement to establish a minimum age for use. The duration of immunity is unknown. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.

Safety in pregnant animals is unknown.

Tetanus Toxoid is prepared by detoxifying tetanus toxin in such a manner as to allow the antigenic properties to remain intact. Product is purified, concentrated and adjuvanted to provide a low dose effective immunizing agent.

Each serial is tested for purity, safety, and potency in accordance with USDA requirements.

Tetanus is caused by a neurotoxin produced by growth of Clostridium tetani, an anaerobic (lives without air) micro-organism, in necrotic tissue. Affected animals become stiff, have difficulty swallowing, and have an increased pulse rate. Breathing is labored. Spasmodic contractions of the muscular system occur, such as contracting muscles of the jaw.

Spasmodic contractions of the muscular system occur, such as contracting muscles of the jaw. Thus, the term “lockjaw” is often used. Legs and tail are often stiff with abdominal muscles contracted. Tetanus stricken animals may be unusually sensitive to light and heat. Temperature of the animal generally remains normal, elevating only shortly before death.

Protective antibody levels usually occur about two weeks after the second injection of the primary immunization series. In contrast, administration of Tetanus Antitoxin is recommended for immediate, emergency, passive treatment of exposed animals with unknown vaccination history or with signs of tetanus infection.

DIRECTIONS: Do not vaccinate within 21 days before slaughter. Store at 2-8° C. Do not freeze. Do not mix with other products. Shake well before use. Use entire contents when first opened.

PRECAUTIONS: A transitory local reaction may occur at injection site. Anaphylactoid reaction may occur following administration of products of this nature. If noted, administer adrenalin or equivalent. In case of human exposure, consult a physician.

DOSAGE & ADMINISTRATION: For primary immunization, two doses should be administered subcutaneously or intramuscularly approximately 30 days apart. Use intramuscularly for horses as local reactions are more likely to occur if injected subcutaneously.

Horses: 1 ml IM

Cattle: 1 ml SC or IM

Sheep, Goats, Swine: 0.5 ml SC or IM

Historically, annual single dose revaccination has been recommended. Contact veterinarian for advice.

OTHER INFORMATION: Contains thimerosal and formalin as preservatives. Tetanus Toxoid Concentrate is available in single dose size packaged 10 vials to the carton, and in 10 dose vials.

THE PEAK OF QUALITY SINCE 1923

VLN: 188 / PCN: 8601.00

COLORADO SERUM COMPANY, 4950 York Street, Denver, Colorado 80216

303-295-752

www.colorado-serum.com

Contact us for information on other Colorado Serum Company products. Fine Veterinary Products since 1923.

FOR VETERINARY USE ONLY

 

 

Order #

10 - 1 ml vials

10 - 1 dose vials

11411

10 ml

10 doses

11415

CPN: 1101033.3

Dimensions

Care information

View full details